Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years' Follow-Up

Area of Science:

• Oncology
• Urology

Background:

• Prostate cancer treatment often involves androgen suppression therapy.
• Intermittent androgen suppression (IAS) is an alternative treatment strategy.
• Long-term outcomes and quality of life with IAS require further evaluation.

Purpose of the Study:

• To review the long-term follow-up of a Phase II trial evaluating intermittent androgen suppression for prostate cancer.
• To assess the impact of IAS on patient well-being, sexual function, and disease progression.
• To evaluate the efficacy and safety of IAS in men with locally advanced or recurrent prostate cancer.

Main Methods:

• Prospective Phase II clinical trial involving 87 patients with prostate cancer.
• Treatment initiated with combined androgen blockade, followed by cycles of medication withholding based on PSA levels.
• Long-term follow-up data analyzed for disease progression, survival, and quality of life indicators.

Main Results:

• Fifty patients were followed for a minimum of 3 years, with a mean study duration of 65.5 months.
• Off-treatment periods were associated with improved well-being, libido, and potency.
• Disease progression to androgen independence occurred in 23 patients, with 13 cancer-specific deaths.

Conclusions:

• Intermittent androgen suppression is a viable option for controlling prostate cancer.
• IAS offers an improved quality of life with reduced toxicity and costs compared to continuous therapy.
• Phase II data suggest IAS does not negatively impact patient outcomes, with ongoing trials to confirm survival benefits.